These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20001849)

  • 1. Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access prostate-specific antigen assays.
    Fillée C; Tombal B; Philippe M
    Clin Chem Lab Med; 2010 Feb; 48(2):285-8. PubMed ID: 20001849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?
    Stephan C; Köpke T; Semjonow A; Lein M; Deger S; Schrader M; Miller K; Jung K
    Clin Chem Lab Med; 2009; 47(11):1325-31. PubMed ID: 19778292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.
    Stephan C; Kahrs AM; Klotzek S; Reiche J; Müller C; Lein M; Deger S; Miller K; Jung K
    Clin Chem Lab Med; 2008; 46(5):623-9. PubMed ID: 18839463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA.
    Vignati G; Giovanelli L
    Int J Biol Markers; 2007; 22(4):295-301. PubMed ID: 18161661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers.
    Stephan C; Bangma C; Vignati G; Bartsch G; Lein M; Jung K; Philippe M; Semjonow A; Catalona WJ
    Int J Biol Markers; 2009; 24(2):65-9. PubMed ID: 19634108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
    Garrido MM; Marta JC; Ribeiro RM; Pinheiro LC; Holdenrieder S; Guimarães JT
    In Vivo; 2021; 35(6):3431-3439. PubMed ID: 34697179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection.
    Jansen FH; Roobol M; Bangma CH; van Schaik RH
    Clin Chem; 2008 Dec; 54(12):1999-2006. PubMed ID: 18927249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant prostate specific antigen test results despite WHO assay standardization.
    Boegemann M; Arsov C; Hadaschik B; Herkommer K; Imkamp F; Nofer JR; Gerß J; Albers P; Semjonow A
    Int J Biol Markers; 2018 Aug; 33(3):275-282. PubMed ID: 29734838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.
    Stephan C; Klaas M; Müller C; Schnorr D; Loening SA; Jung K
    Clin Chem; 2006 Jan; 52(1):59-64. PubMed ID: 16391327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
    de la Taille A; Houlgatte A; Houdelette P; Goluboff ET; Berlizot P; Ricordel I
    Br J Urol; 1998 Sep; 82(3):389-92. PubMed ID: 9772876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.
    Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G
    BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Exploration and validation of optimal cut-off values for tPSA and fPSA/tPSA screening of prostate cancer at different ages].
    Liu XM; Duan HY; Zhang DQ; Chen C; Ji YT; Zhang YM; Feng ZW; Liu Y; Li JJ; Zhang Y; Li CY; Zhang YC; Yang L; Lyu ZY; Song FF; Song FJ; Huang YB
    Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):354-364. PubMed ID: 38644271
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.
    Stephan C; Kahrs AM; Cammann H; Lein M; Schrader M; Deger S; Miller K; Jung K
    Prostate; 2009 Feb; 69(2):198-207. PubMed ID: 18942119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of assay methods for total and free PSA after WHO standardization.
    Foj L; Filella X; Alcover J; Augé JM; Escudero JM; Molina R
    Tumour Biol; 2014 Mar; 35(3):1867-73. PubMed ID: 24092573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.